Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
University of Zurich researchers reported in Science Advances on October 9, 2026 that red blood cells coupled to the disease-inducing peptide prevented experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis, when given beforehand and eased symptoms when given after onset. The effect was specific to the coupled peptide and depended on both cell and peptide dose. Kupffer cells, immune cells in the liver that swallowed the coated red cells, were required for tolerance. The authors describe red cells coupled to a cocktail of multiple sclerosis peptides as a promising approach for patients, but these results are from mice.
Researchers reported in Nature Communications on October 9, 2026 that the corn pathogen Ustilago maydis secretes a protein, Pit2, that plant enzymes cut to release a hidden peptide, which then activates the fungal receptor Gpe1 and promotes fungal growth after the fungus enters plant tissue. Mutations that disrupted the peptide-receptor contact reduced virulence, and the system is conserved in related fungi. The authors note mechanistic similarities to mammalian GPCRs, the receptor family targeted by many peptide drugs.
Researchers at Tufts University and UT Southwestern reported in Obesity Science & Practice on October 7, 2026 a pilot randomized trial of 39 adults who had lost weight on GLP-1 drugs and were stopping them, assigned to usual care (14), a digital wellness app (12), or medically tailored meals (13). Over the first four months off the drug, both the app and meal groups gained less weight than the control group, by 7.16 and 7.17 percentage points of body weight. Weight was an exploratory outcome, measured with Bluetooth scales at home, and the authors said larger and longer trials are needed.
A UT Southwestern study published October 7, 2026 in Diabetes, Obesity and Metabolism compared 73,592 matched pairs of veterans with type 2 diabetes who started a GLP-1 drug or a DPP-4 inhibitor, an older diabetes pill, between 2006 and 2021. Over about 27 months, the GLP-1 group had a 13% lower fall rate (incidence rate ratio 0.87) and slightly less worsening on a frailty index. The link weakened in people who were already severely frail, and the observational design cannot prove the drugs caused the difference.
Researchers at Hebrew University and Hadassah Medical Center reported in Diabetes, Obesity and Metabolism on October 7, 2026 a records study of 4,554 matched adults with type 2 diabetes and stage 3 or 4 chronic kidney disease who started a GLP-1 drug or tirzepatide, or finerenone, a non-steroidal kidney drug. Kidney failure or dialysis occurred in 4.8% versus 6.0% within 2.5 years (hazard ratio 0.71), but the absolute risk difference of 1.14 percentage points was not statistically clear. Albuminuria, a key kidney measure, was missing for most people, so the authors warned of residual confounding.
A University of Michigan simulation published October 7, 2026 in Obesity modeled Black and White adults aged 65 to 70 with a BMI of 35 or higher and cardiovascular disease over 25 years. Compared with no treatment, semaglutide 2.4 mg cost $7,300 and sleeve gastrectomy $12,100 per quality-adjusted life year gained, and surgery cost $53,700 per extra quality-adjusted year compared with semaglutide, within the model's $100,000 threshold. Surgery was the most cost-effective option in 57% of simulations; semaglutide was slightly more equitable between the two groups but not enough to change the ranking.
Doctors in Illinois and Michigan described in JAAD Case Reports a 46-year-old man with a history of melanoma who began daily injections of Melanotan II, an unapproved tanning peptide, bought at a local gym, Gizmodo reported on October 8, 2026. About five weeks later he noticed moles changing size, shape, and color and stopped; a biopsy about a month after that confirmed an early-stage melanoma. He also used tanning beds two to three times a week and had taken anabolic steroids, so the authors could not rule out other causes, and they warned about unregulated peptides promoted on social media.
Researchers at the First Affiliated Hospital of Soochow University in China reported in the Journal of Nuclear Medicine on October 8, 2026 a gallium-68 tracer built on a dimeric (two-unit) cyclic peptide, [68Ga]Ga-TDN1, that binds nectin-4, a tumor protein also targeted by the antibody-drug conjugate enfortumab vedotin (Padcev). After animal tests showed specific tumor uptake, a first-in-human pilot in six breast cancer patients found it performed comparably to standard FDG PET for primary tumors and lymph nodes and detected bone and liver metastases better. The tracer was well tolerated; the human study is very small.
Researchers at Fujian Medical University reported in Bioconjugate Chemistry on October 8, 2026 that they used the PepMimic AI platform to design TR23, a peptide designed by mimicking a protein binding interface, and labeled it with gallium-68 for PET imaging. The tracer bound TROP-2, a protein common in many solid tumors and the target of the antibody-drug conjugate Trodelvy, with nanomolar strength, and gave clear, specific tumor signals in pancreatic, prostate, and thyroid cancer models in mice, with signal strength tracking TROP-2 levels in tissue. The work is preclinical.
University of Pennsylvania researchers reported in JAMA Network Open on October 7, 2026 that among 47.9 million adults eligible for obesity medicines in Epic Cosmos, a database of health records from more than 2,000 U.S. hospitals, 148,792 started oral semaglutide between December 22, 2025, when the FDA approved the pill for obesity, and March 15, 2026: 87.6% on the Wegovy pill and 12.4% on Rybelsus. Weekly starts peaked at 4.56 per 10,000 eligible adults in early March, briefly exceeding starts of injectable semaglutide, and 53.0% of people starting the pill had never used a GLP-1 drug before. Compared with people starting injections, pill users were older on average, more often women (72.7%), and had a lower average BMI (36.6); the study counted prescription orders, which may not all have been filled.
Physicians at University Hospital Zurich described in BMJ Case Reports on October 7, 2026 a woman in her mid-20s who was admitted after five days of nausea, repeated vomiting, and loose stools that did not stop with IV fluids and three anti-nausea drugs. After repeated questioning, she said that in a wellness setting a self-described life coach with no medical training had given her four weekly, rising doses of an unverified product said to contain retatrutide, Eli Lilly's experimental GLP-1, GIP, and glucagon drug; she had not thought of the shots as medicine. She improved two days after admission and recovered within a week, a standard scale rated the product as the probable cause, and the authors urge doctors to ask directly about injections, peptides, and research chemicals.
Researchers at Zhejiang University of Technology in China and Egypt's National Research Centre reported in the Journal of Medicinal Chemistry on October 7, 2026 a deep-learning model, SMAMP, that reads peptides as full chemical structures, so it can handle unnatural amino acids and end-group changes that sequence-based models miss. Of 19 very short peptides designed with its help, 13 killed bacteria, and the model's predicted potency against E. coli tracked lab measurements (correlation 0.764). Two leads, HP-1 and HP-2, were strongly bactericidal with low toxicity to mammalian cells, led to less resistance than standard antibiotics in lab tests, protected wax moth larvae from infection, and helped wounds heal in mice.
Researchers at Kumamoto University in Japan reported in Molecular Pharmaceutics on October 7, 2026 a small ring-shaped peptide, called SLS, that can be built into an antibody's genetic code to help it reach the brain. Attaching one SLS peptide to each heavy chain of the breast cancer antibody trastuzumab increased its passage across lab models of the blood-brain barrier and raised its brain levels after intravenous injection in mice, while its blood levels and its ability to kill HER2-positive cancer cells stayed about the same. The tag also raised brain delivery of the Alzheimer's antibody aducanumab; the work so far is in cells and mice.
At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.
A retrospective study from two centers in Palermo, Italy, published online September 25, 2026 in the Journal of Diabetes and Its Complications and reported by News-Medical on October 2, followed 122 adults with overweight or obesity and no diabetes who took tirzepatide alongside a standardized low-carbohydrate diet and tailored exercise. After 24 weeks, at a mean final dose of 5.32 mg, average weight fell from 95 kg to 80 kg, fat mass fell 35.4% and fat-free mass 5.1% on bioelectrical impedance, and the authors reported that skeletal muscle was preserved. The study had no control group, used bioimpedance rather than DXA scans, and included only people who completed the 24 weeks.
An online survey of 760 U.S. hepatologists and gastroenterologists, endocrinologists, and primary care clinicians, conducted from November 2024 to January 2025 and published October 6, 2026 in Clinical and Translational Gastroenterology, found that 76.8% were very or extremely familiar with the GLP-1 receptor, compared with 53.9% for the GIP receptor and 30.1% for the glucagon receptor. Most still expected each type of agonist to help people with MASH: 90.3% for GLP-1, 75.9% for GIP, and 87.0% for glucagon receptor agonists. One author is a Boehringer Ingelheim employee; Boehringer is developing survodutide, a GLP-1 and glucagon dual agonist, for MASH.
Researchers at Lembas Bio and Tel Aviv University reported in ACS Nutrition Science on October 6, 2026 an AI-guided design pipeline, built on AlphaFold2 structural modeling, for peptides that act on nutrient-sensing receptors of the gut cells that release the hormone GLP-1. After four rounds of design and screening, lead peptides raised GLP-1 secretion more than 27-fold in a mouse gut cell line, exceeding an optimized small-molecule GLP-1 secretagogue, and 28 days of oral dosing reduced food intake and body weight in diet-induced obese rats, with semaglutide as an active comparator. The authors present the work as a route to nutritional ingredients, and the results so far come from cells and rats.
A University of Pennsylvania psychiatry team reported in Diabetes, Obesity and Metabolism on October 6, 2026 that neurons carrying the amylin-responsive calcitonin receptor in the laterodorsal tegmental nucleus, a brainstem region tied to reward and motivation, project to the ventral tegmental area in both mice and rats. Knocking down the receptor along that pathway weakened the appetite-suppressing effect of injected salmon calcitonin, which activates amylin receptors, and chemically switching the pathway on reduced food intake and body weight in mice. The findings come from rodents and help explain how amylin signaling reduces food intake.